Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,551-1,600 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__87_B5,16 | Lung | Primary cancer | 3,073 | Tumor/Malignant | 39.1% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__87_B5,17 | Lung | Primary cancer | 1,838 | Tumor/Malignant | 41.4% | 0.91 | 0.28 |
| NSCLC_38242124__IMC__87_B5,2 | Lung | Primary cancer | 2,093 | Tumor/Malignant | 39.4% | 0.90 | 0.30 |
| NSCLC_38242124__IMC__87_B5,3 | Lung | Primary cancer | 3,330 | Tumor/Malignant | 50.5% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__87_B5,4 | Lung | Primary cancer | 4,056 | Tumor/Malignant | 69.7% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__87_B5,5 | Lung | Primary cancer | 4,838 | Tumor/Malignant | 48.3% | 0.87 | 0.36 |
| NSCLC_38242124__IMC__87_B5,6 | Lung | Primary cancer | 2,629 | Tumor/Malignant | 67.2% | 0.95 | 0.15 |
| NSCLC_38242124__IMC__87_B5,7 | Lung | Primary cancer | 5,015 | Tumor/Malignant | 72.6% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__87_B5,8 | Lung | Primary cancer | 3,832 | Tumor/Malignant | 52.9% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__87_B6,1 | Lung | Primary cancer | 3,925 | Tumor/Malignant | 74.5% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_B6,10 | Lung | Primary cancer | 3,533 | Stromal | 45.4% | 0.90 | 0.32 |
| NSCLC_38242124__IMC__87_B6,11 | Lung | Primary cancer | 3,555 | Tumor/Malignant | 51.0% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__87_B6,12 | Lung | Primary cancer | 3,804 | Tumor/Malignant | 31.1% | 0.94 | 0.23 |
| NSCLC_38242124__IMC__87_B6,13 | Lung | Primary cancer | 4,404 | Immune | 38.0% | 0.95 | 0.20 |
| NSCLC_38242124__IMC__87_B6,14 | Lung | Primary cancer | 2,764 | Tumor/Malignant | 59.6% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__87_B6,15 | Lung | Primary cancer | 3,800 | Stromal | 32.6% | 0.63 | 0.76 |
| NSCLC_38242124__IMC__87_B6,16 | Lung | Primary cancer | 3,370 | Tumor/Malignant | 29.4% | 0.89 | 0.29 |
| NSCLC_38242124__IMC__87_B6,17 | Lung | Primary cancer | 3,543 | Tumor/Malignant | 62.3% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__87_B6,2 | Lung | Primary cancer | 1,932 | Immune | 24.7% | 0.43 | 0.97 |
| NSCLC_38242124__IMC__87_B6,3 | Lung | Primary cancer | 1,848 | Tumor/Malignant | 40.0% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_B6,4 | Lung | Primary cancer | 4,237 | Tumor/Malignant | 86.1% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__87_B6,5 | Lung | Primary cancer | 5,070 | Tumor/Malignant | 28.3% | 0.85 | 0.41 |
| NSCLC_38242124__IMC__87_B6,6 | Lung | Primary cancer | 2,534 | Tumor/Malignant | 59.7% | 0.95 | 0.21 |
| NSCLC_38242124__IMC__87_B6,7 | Lung | Primary cancer | 4,179 | Stromal | 61.7% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__87_B6,8 | Lung | Primary cancer | 3,449 | Tumor/Malignant | 53.6% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__87_B6,9 | Lung | Primary cancer | 3,163 | Immune | 26.8% | 0.41 | 0.93 |
| NSCLC_38242124__IMC__87_B7,1 | Lung | Primary cancer | 3,258 | Tumor/Malignant | 45.7% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__87_B7,10 | Lung | Primary cancer | 5,361 | Tumor/Malignant | 84.0% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__87_B7,11 | Lung | Primary cancer | 3,962 | Tumor/Malignant | 78.6% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__87_B7,12 | Lung | Primary cancer | 1,054 | Stromal | 39.4% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__87_B7,13 | Lung | Primary cancer | 258 | Tumor/Malignant | 72.5% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B7,14 | Lung | Primary cancer | 3,100 | Tumor/Malignant | 36.2% | 0.91 | 0.25 |
| NSCLC_38242124__IMC__87_B7,15 | Lung | Primary cancer | 3,931 | Tumor/Malignant | 40.4% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B7,2 | Lung | Primary cancer | 3,415 | Tumor/Malignant | 62.1% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__87_B7,3 | Lung | Primary cancer | 3,574 | Tumor/Malignant | 82.6% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_B7,4 | Lung | Primary cancer | 3,143 | Tumor/Malignant | 62.0% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__87_B7,5 | Lung | Primary cancer | 3,066 | Tumor/Malignant | 47.1% | 0.88 | 0.31 |
| NSCLC_38242124__IMC__87_B7,6 | Lung | Primary cancer | 2,135 | Tumor/Malignant | 73.3% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B7,7 | Lung | Primary cancer | 3,468 | Tumor/Malignant | 66.7% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__87_B7,8 | Lung | Primary cancer | 2,078 | Tumor/Malignant | 59.4% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__87_B7,9 | Lung | Primary cancer | 2,847 | Tumor/Malignant | 70.1% | 0.97 | 0.14 |
| NSCLC_38242124__IMC__87_B8,1 | Lung | Primary cancer | 3,125 | Tumor/Malignant | 55.5% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_B8,10 | Lung | Primary cancer | 4,837 | Tumor/Malignant | 64.3% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__87_B8,11 | Lung | Primary cancer | 3,758 | Tumor/Malignant | 90.8% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_B8,12 | Lung | Primary cancer | 4,425 | Tumor/Malignant | 84.2% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B8,13 | Lung | Primary cancer | 2,232 | Tumor/Malignant | 73.9% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B8,14 | Lung | Primary cancer | 3,660 | Tumor/Malignant | 40.9% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B8,15 | Lung | Primary cancer | 3,908 | Tumor/Malignant | 75.2% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B8,16 | Lung | Primary cancer | 3,067 | Tumor/Malignant | 31.8% | 0.82 | 0.49 |
| NSCLC_38242124__IMC__87_B8,17 | Lung | Primary cancer | 2,724 | Tumor/Malignant | 35.2% | 0.96 | 0.15 |